Shanghai Henlius Biotech $2696.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS35
PHASE 3 / 2-313
RECRUITING18
READOUTS ≤12 MONTHS15
READOUT SLIPPED >6 MO14%
Delay Index: of 21 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shanghai Henlius Biotech on the live radar map → 📅 $2696.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HLX10 NCT04301739 |
P3 | Not yet recruiting | Triple Negative Breast Cancer | 522 | 2022-09-07 |
| HLX11 NCT05346224 |
P3 | Active, not recruiting | Breast Cancer; Breast Neoplasms | 900 | 2024-05-15 (+5 mo) |
| HLX10 NCT04547166 |
P2/3 | Recruiting | Metastatic Colorectal Cancer | 568 | 2025-09-24 |
| HLX26 NCT05787613 |
P2 | Active, not recruiting | NSCLC Stage IV | 132 | 2026-02 (+7 mo) |
| Serplulimab + chemotherapy (carboplatin-etoposide) NCT05468489 |
P2 | Active, not recruiting | Extensive Stage Small Cell Lung Cancer | 200 | 2026-02-28 (+21 mo) |
| HLX10 NCT05353257 |
P3 | Active, not recruiting | Limited-Stage Small Cell Lung Cancer | 511 | 2026-06-30 (+18 mo) |
| HLX43 DOSE 1 NCT07269782 |
P2 | Recruiting | Non Small Cell Lung Cancer | 60 | 2026-07-10 |
| HLX10+chemo NCT06812260 |
P2 | Active, not recruiting | SCLC, Extensive Stage | 26 | 2026-10-22 (+2 mo) |
| HLX43 dose 1 NCT06848699 |
P1/2 | Recruiting | Solid Tumor Cancer; Non Small Cell Lung Cancer | 105 | 2026-10-30 |
| HLX43 DOSE 1 NCT06742892 |
P2 | Recruiting | Carcinoma, Hepatocellular | 90 | 2026-10-31 |
| HLX43 NCT06769113 |
P2 | Recruiting | Esophageal Cancer | 102 | 2026-10-31 |
| HLX43 DOSE 1 NCT06839066 |
P2 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 70 | 2026-11-22 |
| HLX43 NCT07459738 |
P2 | Not yet recruiting | Hormone Receptor Positive HER-2 Negative Breast Cancer | 60 | 2026-12-30 |
| HLX43 Dose 1; NCT07106892 |
P2 | Recruiting | Colorectal Cancer (CRC) | 60 | 2026-12-30 |
| HLX43 NCT06769152 |
P2 | Recruiting | Cervical Cancer; Ovarian Cancer | 190 | 2026-12-31 (+2 mo) |
| NCT07038382 NCT07038382 |
P2 | Recruiting | Membranous Nephropathy; Lupus Nephritis (LN) | 24 | 2027-01 |
| HLX53 (1000mg) NCT06349980 |
P2 | Recruiting | Carcinoma, Hepatocellular | 117 | 2027-02-10 |
| HLX17 NCT06847334 |
P3 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 772 | 2027-04-09 |
| HLX43 DOSE 1 IN ≥2L TNBC NCT07487519 |
P2 | Not yet recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 180 | 2027-05-15 |
| HLX22 NCT06832202 |
P2 | Recruiting | HER2-low Hormone Receptor Positive Breast Cancer | 50 | 2027-06-01 |
| HLX22 NCT06532006 |
P3 | Recruiting | Gastroesophageal-junction Cancer; Monoclonal Antibody | 550 | 2027-06-01 |
| HLX13 NCT06841185 |
P3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 656 | 2027-06-06 |
| HLX43 dose 1 NCT07253142 |
P2 | Recruiting | Non Small Cell Lung Cancer; Small Cell Lung Cancer | 120 | 2027-06-18 |
| HLX15-IV NCT06895512 |
P3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 386 | 2027-07 |
| HLX43 dose 1 + HLX07 NCT07358585 |
P1/2 | Not yet recruiting | Colon Cancer Adenocarcinoma | 126 | 2027-07-28 |
| HLX43 DOSE 1 NCT07115485 |
P2 | Recruiting | Gastric or Gastroesophageal Junction Adenocarcinoma | 60 | 2027-08-30 |
| HLX43 DOSE 1 NCT06857279 |
P2 | Recruiting | Carcinoma of Head and/or Neck | 167 | 2027-12-30 (+2 mo) |
| HLX87 + HLX22 NCT07294508 |
P2/3 | Recruiting | HER2 + Breast Cancer | 706 | 2028-01-15 |
| HLX43 DOSE 1 (2.5 mg/kg) NCT07301229 |
P2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 100 | 2028-02-21 |
| HLX22 NCT07824869 |
P2 | Not yet recruiting | HER2 + Breast Cancer | 90 | 2028-03-31 |
| HLX43 DOSE 1 (2.0 mg/kg) NCT06907615 |
P2 | Recruiting | Non Small Cell Lung Cancer | 243 | 2028-04-20 |
| HLX87+HX22 NCT07294534 |
P2/3 | Not yet recruiting | HER2 + Breast Cancer | 817 | 2028-09-30 |
| HLX43 NCT07459751 |
P2/3 | Recruiting | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | 706 | 2030-01-15 |
| Investigational drug: HLX37 dose1, IV, Q3W NCT07865910 |
P2/3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 1438 | 2030-12-30 |
| HLX07 NCT07318883 |
P2/3 | Not yet recruiting | Squamous NSCLC | 720 | 2031-01 |